Michael Benkowitz Sells 22,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $470.95, for a total value of $10,596,375.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Benkowitz also recently made the following trade(s):

• On Tuesday, January 20th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The stock was sold at an average price of $464.66, for a total value of $6,795,652.50.
• On Tuesday, January 20th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The stock was sold at an average price of $464.66, for a total transaction of $3,659,197.50.
• On Monday, January 26th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $471.91, for a total transaction of $10,617,975.00.
• On Monday, January 12th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.51, for a total transaction of $10,788,975.00.
• On Monday, January 5th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The stock was sold at an average price of $487.38, for a total transaction of $3,838,117.50.
• On Monday, January 5th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total transaction of $7,127,932.50.
• On Monday, December 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $502.79, for a total transaction of $11,312,775.00.
• On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $514.35, for a total transaction of $11,572,875.00.
• On Monday, December 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $496.30, for a total value of $11,166,750.00.
• On Monday, December 8th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $478.58, for a total value of $10,768,050.00.

United Therapeutics Price Performance

UTHR stock opened at $482.59 on Thursday. The stock has a market capitalization of $20.78 billion, a P/E ratio of 18.29, a P/E/G ratio of 2.54 and a beta of 0.85. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99. The business has a fifty day moving average price of $486.95 and a 200-day moving average price of $424.86.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds have recently modified their holdings of UTHR. Darwin Global Management Ltd. purchased a new stake in shares of United Therapeutics in the third quarter worth $317,617,000. Norges Bank purchased a new stake in United Therapeutics in the 2nd quarter worth $136,453,000. Invesco Ltd. raised its holdings in United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after acquiring an additional 419,588 shares during the period. AQR Capital Management LLC lifted its position in shares of United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after acquiring an additional 364,713 shares in the last quarter. Finally, Baillie Gifford & Co. bought a new position in shares of United Therapeutics in the fourth quarter worth about $157,390,000. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of research analyst reports. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. HC Wainwright boosted their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Morgan Stanley set a $447.00 price target on United Therapeutics in a research note on Wednesday, October 29th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $509.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.